Semax

What it is

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from a fragment of adrenocorticotropic hormone, specifically ACTH(4-10), with a stabilizing Pro-Gly-Pro tripeptide added to its C-terminus to resist enzymatic breakdown.¹ It was designed to keep ACTH(4-10)'s reported cognitive and neuroprotective effects while shedding ACTH's classic hormonal, adrenal-stimulating activity. Despite the ACTH-derived backbone, Semax isn't classified as a corticosteroid or hormone — it's studied and marketed as a nootropic and neuroprotective peptide.

Semax is a Russian-developed compound, and this matters for how its evidence should be read. It was synthesized in 1982 by researchers including Nikolai Myasoedov and Igor Ashmarin at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow.¹ It underwent Soviet- and later Russian-era development and remains almost entirely a product of the Russian and CIS pharmaceutical and academic research tradition. The large majority of published human studies on Semax are Russian-language publications in Russian medical journals — Semax has essentially no history of Western pharmaceutical development or FDA review.

It's also known as N-Acetyl Semax (an acetylated variant sold in some research-chemical products). In Russia, it's marketed under the brand name "Semax" as a 0.1% nasal solution.

How it works

Semax's mechanism is multi-pathway and not fully mapped, but several effects recur consistently across the largely animal literature. The most frequently cited mechanistic finding involves brain-derived neurotrophic factor (BDNF): a single 50 μg/kg dose in rats produced a 1.4-fold increase in hippocampal BDNF protein, a 1.6-fold increase in TrkB receptor phosphorylation, and 2–3 fold increases in BDNF and TrkB mRNA, alongside improved performance on conditioned avoidance learning tasks.³

Preclinical work also reports activation of dopaminergic and serotonergic signaling, and genome-wide transcriptional studies in rodent models of focal cerebral ischemia found Semax alters expression of genes tied to immune response, inflammation, and vascular function. A 2025 in vitro study found Semax has high affinity for Cu(II) ions and can pull copper out of copper–amyloid-beta complexes, reducing copper-catalyzed reactive oxygen species and providing measurable cytoprotection to neuroblastoma cells exposed to oxidative stress — a finding of interest for Alzheimer's-related research, though still preclinical.⁴ A separate 2025 study examined Semax's effect on intracellular calcium dynamics in rat pyramidal neurons, reporting modulation of spontaneous calcium fluctuations.⁵

The Pro-Gly-Pro addition significantly extends Semax's resistance to peptidase degradation relative to unmodified ACTH(4-10) — this is the entire design rationale. Even so, as a peptide, it does not survive oral administration and is not orally bioavailable. Precise human plasma half-life figures aren't well established in the widely available English-language literature; reported pharmacodynamic effects (EEG changes, cognitive test performance) appear to outlast rapid plasma clearance, consistent with a receptor- or gene-expression-mediated mechanism rather than sustained plasma exposure. Intranasal administration is by far the dominant and clinically studied route, both in the Russian-approved formulation and in essentially all research protocols; no injectable, oral, or topical Semax product has meaningful clinical study behind it.

What the research shows

Animal / preclinical evidence

The foundational mechanistic paper linking Semax to BDNF/TrkB upregulation and improved avoidance-learning performance is a 2006 rat study.³ More recent (2025) in vitro and rodent electrophysiology studies have examined Semax's copper-chelating antioxidant activity and its effects on intracellular calcium dynamics, both relevant to neuroprotection research but neither a clinical trial.⁴⁵ Preliminary rodent Alzheimer's-disease-model research has also reported that Semax and its derivatives improved measures of cognitive function and affected copper-induced amyloid-beta aggregation in model systems — again, animal and in vitro work, not human trial data.

Human evidence

Semax's foundational human trial is a 1997 study of 30 patients with acute ischemic hemispheric stroke given Semax as an adjunct to conventional therapy, compared against 80 historical controls.² It reported improved regression of general cerebral and focal, especially motor, neurological deficits, with the most effective doses cited as 12 mg/day (moderate stroke) and 18 mg/day (severe stroke) for 5–10 days. This is one of the foundational trials behind Semax's Russian stroke-recovery approval, but it used a historical rather than a randomized concurrent control group — a real methodological limitation.

Secondary sources also describe a larger randomized trial (n≈184) reportedly published in a major stroke journal, comparing Semax 0.1% intranasal solution against placebo in acute ischemic stroke and reporting improvements on standard stroke outcome scales. This specific citation could not be independently verified against the primary journal record during this review and should be treated as unconfirmed — it's flagged here as an example of the broader problem of secondary "peptide research" sites misciting the Semax literature, and readers should look for the primary source before treating it as settled.

Reported healthy-volunteer studies describe Semax at 250–1000 mcg/kg improving attention and short-term memory with accompanying EEG changes, though full peer-reviewed citation details for this specific claim also weren't independently verified to PubMed and should be treated cautiously.

Honest assessment: Semax has a more genuine research foundation than many unapproved peptides — it's an approved Russian pharmaceutical with decades of use in that market and legitimate mechanistic studies, particularly the BDNF/TrkB work, published in indexed international journals. But the pivotal efficacy trials behind its stroke and cognitive-disorder indications are substantially Russian-language, often use small samples or historical controls, and haven't been replicated in large, independent, English-language, randomized controlled trials meeting contemporary international standards. No FDA drug application for Semax has been pursued or approved. "Semax improves cognition or stroke recovery" should be read as an evidence-based hypothesis with real but geographically and methodologically limited support — not as an internationally settled clinical fact.

Typical use and dosing

Published dosing comes from two distinct sources that shouldn't be conflated: Russia's approved clinical formulation, and patterns reported in online research and biohacking communities.

These community figures are drawn from vendor and biohacking-forum material, not from controlled human dose-ranging trials conducted to modern regulatory standards, and shouldn't be interpreted as validated or safe dosing guidance.

Safety, side effects, and who should avoid it

In Russian clinical literature, Semax is generally described as well tolerated, with mild and transient local nasal irritation being the most commonly reported adverse effect; serious adverse events weren't prominently reported in the available trial literature. But the rigor of adverse-event reporting in these studies — many open-label, some using historical controls — isn't comparable to a modern FDA-style safety database.

Long-term safety beyond weeks to a few months of use hasn't been established in large, independent, controlled trials, and drug-drug interaction data are minimal. Use in children, pregnancy, and breastfeeding hasn't been rigorously studied outside limited Russian pediatric literature, which isn't considered sufficient by Western regulatory standards. As with other unapproved research peptides, there's no long-term human pharmacovigilance data outside of Russia's own regulatory system, and that system's reporting isn't independently verifiable by US regulators or researchers.

Regulatory status

Semax is not FDA-approved for any indication in the United States, and no New Drug Application has been approved. It's also not currently on FDA's 503A bulk drug substances list, so US compounding pharmacies cannot legally compound it for patient use at this time. Semax was among several peptides FDA's Pharmacy Compounding Advisory Committee (PCAC) discussed at a public meeting on July 24, 2026, evaluating a nomination for inclusion on the 503A list for proposed uses in "cerebral ischemia, migraine, and trigeminal neuralgia."⁶ As of that meeting, this is a nomination under review — FDA hasn't published a final rule, and the outcome wasn't yet public as of this writing.

In the US, Semax is sold almost exclusively as a "research chemical, not for human use" — labeling that exists to sidestep FDA drug-marketing rules while the product is, in practice, purchased by individual consumers for self-administration. Products from unregulated suppliers carry meaningful risk of inaccurate labeling, impurities, and non-sterile preparation for a substance intended to be administered intranasally.

For context, Semax has been an approved, prescription pharmaceutical in Russia since 1998 for stroke recovery and cognitive/neurological indications, and was added to Russia's List of Vital and Essential Drugs in 2011.¹ This Russian approval has no legal bearing on US status, where it remains unapproved.

Semax isn't explicitly named in the WADA Prohibited List's S0, S1, or S2 categories the way TB-500 is. It's a synthetic, non-hormonal neuropeptide, and public anti-doping guidance doesn't identify it as a commonly tested-for substance in the way GH-axis peptides and growth factors are. That said, WADA's S0 "Non-Approved Substances" category is a broad catch-all that can extend to any pharmacological substance lacking government health-authority approval for human therapeutic use, and Semax hasn't been affirmatively cleared as permissible.⁸ Athletes subject to testing should consult their national anti-doping organization directly rather than assume any unlisted peptide is automatically permitted.

Frequently asked questions